RHEUMATOID arthritis markedly elevates venous thromboembolism risk through continuous systemic inflammation, endothelial dysfunction, and sustained hypercoagulability. Comprehensive epidemiological data indicate that individuals diagnosed with rheumatoid arthritis experience a 50% to 100% excess risk of deep vein thrombosis and pulmonary embolism compared to the general population. Absolute incidence rates range between 3 and 6 events per 1,000 person-years, with the greatest thrombotic vulnerability occurring during the first year following initial diagnosis. Although relative risk gradually declines as therapeutic management begins, the elevated vascular risk persists across the entire clinical course.
The biological processes driving venous thromboembolism in rheumatoid arthritis stem from a complex interplay between chronic systemic inflammation and the coagulation cascade. Proinflammatory mediators including interleukin-1, interleukin-6, and tumor necrosis factor stimulate vascular tissue factor expression while downregulating natural anticoagulant pathways such as the protein C system and tissue factor pathway inhibitor. Concurrently, persistent immune activation causes microvascular injury that progresses to sustained endothelial dysfunction, increasing vascular permeability and accelerating leukocyte adhesion. Activated platelets release extracellular vesicles into circulation and synovial compartments, which amplify localized cytokine production and provide procoagulant membranes that enhance thrombin generation. Elevated concentrations of acute-phase reactants, particularly fibrinogen, increase blood viscosity and work synergistically with immobility to produce venous stasis.
Disease activity serves as a critical determinant of vascular outcomes in clinical practice. Patients exhibiting high disease activity have approximately twice the risk of developing venous thromboembolism compared to those achieving clinical remission. However, even patients maintaining remission retain a 35% excess risk relative to healthy individuals, indicating that cumulative disease damage and persistent subclinical inflammation continue to influence vascular integrity. Pharmacological choices also impact patient safety profiles. Systemic glucocorticoid exposure independently increases thrombotic risk in a dose-dependent manner, highlighting the clinical value of minimizing steroid dosage and duration. Conventional synthetic disease-modifying antirheumatic drugs and biologic tumor necrosis factor inhibitors maintain reassuring safety records, while targeted Janus kinase inhibitors warrant comprehensive, individualized cardiovascular and thrombotic assessments.
Reference
Vojinovic T et al. The risk of venous thromboembolism in RA. Rheumatology. 2026;65(8):keag388.
Featured Image: Solarisys on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
